Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:50PM ET
13.82
Dollar change
+0.36
Percentage change
2.65
%
IndexRUT P/E- EPS (ttm)-1.97 Insider Own40.53% Shs Outstand54.87M Perf Week-5.26%
Market Cap931.35M Forward P/E- EPS next Y-1.90 Insider Trans-0.38% Shs Float40.07M Perf Month17.64%
Income-100.70M PEG- EPS next Q-0.42 Inst Own60.13% Short Float17.29% Perf Quarter51.23%
Sales0.00M P/S- EPS this Y12.10% Inst Trans-0.30% Short Ratio12.50 Perf Half Y114.97%
Book/sh4.08 P/B3.38 EPS next Y-10.55% ROA-39.88% Short Interest6.93M Perf Year192.23%
Cash/sh3.09 P/C4.47 EPS next 5Y- ROE-45.11% 52W Range4.69 - 16.65 Perf YTD50.24%
Dividend Est.- P/FCF- EPS past 5Y-22.33% ROI-43.49% 52W High-16.98% Beta1.03
Dividend TTM- Quick Ratio10.39 Sales past 5Y0.00% Gross Margin- 52W Low194.72% ATR (14)0.89
Dividend Ex-Date- Current Ratio10.39 EPS Y/Y TTM12.32% Oper. Margin0.00% RSI (14)51.85 Volatility5.53% 7.37%
Employees100 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.12 Target Price19.57
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q4.97% Payout- Rel Volume0.52 Prev Close13.47
Sales Surprise- EPS Surprise-2.62% Sales Q/Q- EarningsMar 11 AMC Avg Volume554.30K Price13.82
SMA20-5.22% SMA5010.46% SMA20055.36% Trades Volume236,978 Change2.65%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Initiated Cantor Fitzgerald Overweight
Sep-22-23Initiated Wedbush Outperform $8
Mar-23-23Upgrade H.C. Wainwright Neutral → Buy $16
Mar-21-23Upgrade Guggenheim Neutral → Buy $15
Mar-16-23Upgrade Oppenheimer Perform → Outperform $14
Jul-18-22Resumed Oppenheimer Perform
Apr-04-22Upgrade Citigroup Neutral → Buy $7 → $10
Mar-25-22Downgrade H.C. Wainwright Buy → Neutral
Mar-22-22Downgrade Oppenheimer Outperform → Perform
Mar-22-22Downgrade Guggenheim Buy → Neutral
Mar-26-24 09:55AM
Mar-12-24 09:01PM
Mar-11-24 04:05PM
Mar-08-24 05:01PM
Mar-06-24 04:30PM
04:30PM Loading…
Mar-05-24 04:30PM
Mar-01-24 04:30PM
Feb-14-24 04:30PM
Feb-09-24 02:23AM
Feb-08-24 08:50AM
Feb-02-24 04:30PM
Feb-01-24 03:05PM
Jan-31-24 04:30PM
Jan-23-24 08:50AM
Jan-22-24 08:30AM
12:31PM Loading…
Jan-09-24 12:31PM
Jan-08-24 08:30AM
Jan-02-24 04:30PM
Dec-11-23 12:00PM
Dec-05-23 09:11AM
Dec-01-23 04:30PM
Nov-09-23 04:30PM
Nov-06-23 05:22PM
04:10PM
Nov-03-23 04:30PM
Nov-02-23 09:00AM
Oct-21-23 07:30AM
Oct-17-23 04:30PM
Oct-16-23 12:00PM
Oct-06-23 04:30PM
04:30PM Loading…
Sep-20-23 04:30PM
Sep-01-23 04:30PM
Aug-30-23 04:30PM
Aug-10-23 04:05PM
Aug-04-23 04:30PM
Jun-26-23 01:04PM
08:30AM
Jun-02-23 04:15PM
May-31-23 04:10PM
May-28-23 09:28AM
May-08-23 04:05PM
May-05-23 04:15PM
Apr-25-23 04:30PM
06:35AM
Apr-18-23 04:15PM
Mar-31-23 08:40AM
Mar-29-23 07:53PM
Mar-16-23 04:05PM
03:10AM
Mar-14-23 04:30PM
Mar-06-23 04:15PM
Feb-03-23 04:30PM
Feb-01-23 04:30PM
04:25PM
Jan-27-23 08:41AM
Jan-09-23 08:00AM
Jan-03-23 04:30PM
Dec-22-22 11:35AM
08:38AM
07:54AM
Dec-21-22 05:48PM
Dec-19-22 08:13AM
Dec-13-22 08:00AM
Nov-08-22 04:10PM
Nov-07-22 04:05PM
Nov-03-22 09:00AM
Oct-22-22 08:36AM
Oct-21-22 12:06PM
Oct-14-22 09:37AM
Oct-13-22 12:51PM
Oct-07-22 04:30PM
10:01AM
Sep-28-22 01:47PM
Sep-22-22 10:50AM
Sep-21-22 06:32PM
Sep-13-22 03:45PM
08:44AM
Sep-07-22 01:31PM
Sep-05-22 10:21AM
Sep-01-22 04:15PM
10:17AM
Aug-25-22 11:53AM
11:52AM
Aug-23-22 01:53PM
Aug-20-22 08:28AM
Aug-16-22 10:09AM
Aug-11-22 04:05PM
Jul-11-22 11:00AM
Jun-02-22 04:10PM
May-17-22 04:10PM
May-15-22 08:06AM
Apr-12-22 04:05PM
Mar-31-22 08:33AM
Mar-28-22 04:40PM
Mar-26-22 01:54PM
Mar-23-22 11:40AM
Mar-22-22 11:51AM
09:26AM
Mar-21-22 04:00PM
Mar-17-22 04:30PM
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chacko JacobPRESIDENT AND CEOMar 06 '24Sale16.2140,000648,380728,544Mar 08 04:20 PM
Chacko JacobPRESIDENT AND CEOFeb 07 '24Sale12.2926,042320,186768,544Feb 08 08:01 PM
Chacko JacobPRESIDENT AND CEOFeb 06 '24Sale12.1213,958169,160794,586Feb 08 08:01 PM
Multani Pratik SChief Medical OfficerDec 15 '23Option Exercise0.0014,042029,091Dec 19 07:42 PM
Chacko JacobPresident and CEODec 15 '23Option Exercise0.0038,6670823,083Dec 19 07:39 PM
Chacko JacobPresident and CEODec 15 '23Sale8.5814,539124,813808,544Dec 19 07:39 PM
Multani Pratik SChief Medical OfficerDec 15 '23Sale8.595,28245,35123,809Dec 19 07:42 PM
Piscitelli DominicChief Financial OfficerDec 15 '23Sale8.585,28245,33883,809Dec 19 07:40 PM
Chacko JacobPresident and CEOJul 11 '23Sale8.015,15641,287780,652Jul 11 09:28 PM
Chacko JacobPresident and CEOJul 10 '23Sale8.0110,50884,212785,808Jul 11 09:28 PM
Chacko JacobPresident and CEOJul 05 '23Sale8.014,33634,711796,316Jul 07 04:35 PM
Chacko JacobPresident and CEOJun 26 '23Sale8.0320,000160,562800,652Jun 28 07:18 PM
Last Close
Mar 28 02:50PM ET
8.86
Dollar change
-0.07
Percentage change
-0.78
%
RAPT RAPT Therapeutics Inc daily Stock Chart
IndexRUT P/E- EPS (ttm)-3.05 Insider Own12.10% Shs Outstand34.40M Perf Week4.11%
Market Cap308.33M Forward P/E- EPS next Y-3.10 Insider Trans-0.18% Shs Float30.59M Perf Month2.31%
Income-116.80M PEG- EPS next Q-0.81 Inst Own90.67% Short Float10.78% Perf Quarter-64.39%
Sales0.00M P/S- EPS this Y-9.23% Inst Trans-1.64% Short Ratio2.65 Perf Half Y-47.88%
Book/sh4.27 P/B2.07 EPS next Y6.83% ROA-53.15% Short Interest3.30M Perf Year-50.42%
Cash/sh4.56 P/C1.94 EPS next 5Y- ROE-59.56% 52W Range6.86 - 27.35 Perf YTD-64.35%
Dividend Est.- P/FCF- EPS past 5Y-12.39% ROI-77.10% 52W High-67.61% Beta0.47
Dividend TTM- Quick Ratio7.41 Sales past 5Y-36.87% Gross Margin-243.23% 52W Low29.15% ATR (14)0.87
Dividend Ex-Date- Current Ratio7.41 EPS Y/Y TTM-18.00% Oper. Margin0.00% RSI (14)36.52 Volatility5.27% 6.98%
Employees131 Debt/Eq0.05 Sales Y/Y TTM-100.00% Profit Margin- Recom1.92 Target Price22.00
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q-25.08% Payout- Rel Volume0.22 Prev Close8.93
Sales Surprise- EPS Surprise6.90% Sales Q/Q- EarningsMar 07 BMO Avg Volume1.25M Price8.86
SMA203.01% SMA50-45.37% SMA200-50.75% Trades Volume227,247 Change-0.78%
Date Action Analyst Rating Change Price Target Change
Feb-22-24Downgrade UBS Buy → Neutral $61 → $10
Feb-21-24Downgrade Leerink Partners Outperform → Market Perform $42 → $10
Feb-21-24Downgrade JP Morgan Overweight → Neutral $35 → $15
Feb-21-24Downgrade H.C. Wainwright Buy → Neutral
Feb-20-24Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-16-24Initiated Evercore ISI Outperform
Feb-15-24Initiated Wolfe Research Outperform $39
Sep-14-23Initiated Berenberg Buy $34
Aug-09-23Initiated Stifel Buy $40
Jun-15-23Initiated Barclays Overweight $35
Mar-22-24 05:39AM
Mar-07-24 02:52PM
08:36AM
08:00AM
Mar-05-24 04:30PM
04:03PM Loading…
Feb-20-24 04:03PM
11:22AM
07:58AM
07:39AM
07:30AM
07:17AM
Feb-13-24 08:00AM
Jan-31-24 08:00AM
Jan-02-24 08:00AM
Nov-27-23 08:00AM
07:41PM Loading…
Nov-14-23 07:41PM
Nov-13-23 08:00AM
Nov-03-23 12:00PM
Nov-01-23 04:05PM
Oct-18-23 09:00AM
Sep-27-23 09:24PM
Sep-14-23 09:44AM
Aug-30-23 04:05PM
Aug-16-23 09:55AM
Aug-11-23 08:00AM
Aug-09-23 10:26AM
Aug-08-23 06:03AM
Jun-07-23 08:00AM
May-25-23 05:00PM
May-11-23 08:00AM
08:00AM Loading…
May-03-23 08:00AM
Apr-26-23 04:19PM
Mar-29-23 08:00AM
Mar-21-23 08:50AM
Mar-14-23 08:00AM
Mar-02-23 10:00AM
Feb-28-23 08:00AM
Feb-27-23 09:55AM
Feb-23-23 08:50AM
Feb-22-23 06:31AM
Feb-16-23 04:02AM
Feb-10-23 09:55AM
Feb-07-23 08:00AM
Jan-31-23 05:43PM
Jan-25-23 08:50AM
Jan-03-23 08:00AM
Dec-30-22 09:55AM
Dec-17-22 08:56AM
Dec-08-22 06:30AM
Nov-30-22 07:05PM
Nov-22-22 08:46AM
Nov-17-22 09:38PM
04:24PM
09:55AM
Nov-12-22 07:42AM
Nov-10-22 09:15AM
08:00AM
Nov-09-22 08:00AM
Oct-12-22 07:50AM
Sep-28-22 08:00AM
Sep-23-22 12:00PM
09:55AM
Sep-15-22 06:17AM
Sep-01-22 09:55AM
Aug-31-22 08:00AM
Aug-16-22 09:55AM
Aug-11-22 09:15AM
08:00AM
Jul-10-22 09:37AM
Jun-20-22 09:25AM
May-25-22 03:01PM
08:00AM
May-23-22 08:00AM
May-11-22 09:15AM
08:00AM
May-09-22 05:15PM
May-05-22 09:25AM
May-04-22 08:00AM
Apr-11-22 08:29AM
Mar-28-22 08:00AM
Mar-10-22 08:00AM
Mar-01-22 11:05AM
Feb-24-22 10:35AM
Feb-09-22 08:00AM
Feb-08-22 01:38PM
Jan-04-22 08:00AM
Nov-29-21 03:04PM
Nov-10-21 06:05PM
04:05PM
Nov-09-21 04:01PM
Nov-08-21 03:00PM
08:00AM
Oct-29-21 09:33AM
Oct-25-21 04:10PM
Oct-18-21 08:00AM
Sep-30-21 09:15AM
Sep-23-21 11:15AM
Sep-20-21 08:00AM
08:00AM
Sep-10-21 04:59PM
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brockstedt Dirk G.CHIEF SCIENTIFIC OFFICERJan 05 '24Sale22.7889820,45627,820Jan 08 05:50 PM
Brockstedt Dirk G.Chief Scientific OfficerDec 29 '23Option Exercise6.188,00049,44027,070Jan 02 04:29 PM
HO WILLIAMChief Medical OfficerDec 21 '23Sale21.682,50054,20015,020Dec 22 02:31 PM
HO WILLIAMChief Medical OfficerNov 28 '23Sale13.721,50020,58017,520Nov 29 02:29 PM
HO WILLIAMChief Medical OfficerOct 03 '23Sale15.772,50039,42518,789Oct 04 06:29 PM
HO WILLIAMChief Medical OfficerAug 18 '23Sale18.922,50047,30021,289Aug 22 12:19 PM
HO WILLIAMChief Medical OfficerJul 28 '23Option Exercise12.004605,52023,789Aug 03 02:34 PM
HO WILLIAMChief Medical OfficerJun 23 '23Option Exercise12.0092011,04023,329Jun 27 12:14 PM
HO WILLIAMChief Medical OfficerApr 19 '23Sale18.885,00094,40020,992Apr 20 02:17 PM
HO WILLIAMChief Medical OfficerApr 13 '23Option Exercise12.004605,52022,381Apr 14 06:25 PM